{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:41:27Z","timestamp":1783528887777,"version":"3.55.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"crossref","award":["R272-2017-4040"],"award-info":[{"award-number":["R272-2017-4040"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002739","name":"Aarhus Universitets Forskningsfond","doi-asserted-by":"crossref","award":["AUFF-E-2018-7-14"],"award-info":[{"award-number":["AUFF-E-2018-7-14"]}],"id":[{"id":"10.13039\/501100002739","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"crossref","award":["(R230-A13715"],"award-info":[{"award-number":["(R230-A13715"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"crossref","award":["R238-2016-2708"],"award-info":[{"award-number":["R238-2016-2708"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,4]]},"abstract":"<jats:p>The cGAS-STING pathway serves a critical role in anticancer therapy. Particularly, response to immunotherapy is likely driven by both active cGAS-STING signaling that attracts immune cells, and by the presence of cancer neoantigens that presents as targets for cytotoxic T cells. Chromosomal instability (CIN) is a hallmark of cancer, but also leads to an accumulation of cytosolic DNA that in turn results in increased cGAS-STING signaling. To avoid triggering the cGAS-STING pathway, it is commonly disrupted by cancer cells, either through mutations in the pathway or through transcriptional silencing. Given its effect on the immune system, determining the cGAS-STING activation status prior to treatment initiation is likely of clinical relevance. Here, we used combined expression data from 2,307 tumors from five cancer types from The Cancer Genome Atlas to define a novel cGAS-STING activity score based on eight genes with a known role in the pathway. Using unsupervised clustering, four distinct categories of cGAS-STING activation were identified. In multivariate models, the cGAS-STING active tumors show improved prognosis. Importantly, in an independent bladder cancer immunotherapy-treated cohort, patients with low cGAS-STING expression showed limited response to treatment, while patients with high expression showed improved response and prognosis, particularly among patients with high CIN and more neoantigens. In a multivariate model, a significant interaction was observed between CIN, neoantigens, and cGAS-STING activation. Together, this suggests a potential role of cGAS-STING activity as a predictive biomarker for the application of immunotherapy.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The cGAS-STING pathway is induced by CIN, triggers inflammation and is often deficient in cancer. We provide a tool to evaluate cGAS-STING activity and demonstrate clinical significance in immunotherapy response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0047","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:14:20Z","timestamp":1657703660000},"page":"762-771","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9896-1544","authenticated-orcid":true,"given":"Mateo","family":"Soka\u010d","sequence":"first","affiliation":[{"name":"1Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."},{"name":"2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark."},{"name":"3Bioinformatics Research Center, Aarhus University, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9175-0373","authenticated-orcid":true,"given":"Johanne","family":"Ahrenfeldt","sequence":"additional","affiliation":[{"name":"1Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."},{"name":"2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark."},{"name":"3Bioinformatics Research Center, Aarhus University, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Litchfield","sequence":"additional","affiliation":[{"name":"4Tumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.K.","family":"Watkins","sequence":"additional","affiliation":[{"name":"5Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-2517","authenticated-orcid":true,"given":"Michael","family":"Knudsen","sequence":"additional","affiliation":[{"name":"1Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-9851","authenticated-orcid":true,"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[{"name":"1Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."},{"name":"2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-9201","authenticated-orcid":true,"given":"Martin R.","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"6Department of Biomedicine, Aarhus University, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-9587","authenticated-orcid":true,"given":"Nicolai J.","family":"Birkbak","sequence":"additional","affiliation":[{"name":"1Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark."},{"name":"2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark."},{"name":"3Bioinformatics Research Center, Aarhus University, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"795547","DOI":"10.3389\/fonc.2021.795547","article-title":"Immunotherapy in ovarian cancer: thinking beyond PD-1\/PD-L1","volume":"11","author":"Chardin","year":"2021","journal-title":"Front Oncol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/intimm\/dxw019","article-title":"The role of neoantigens in response to immune checkpoint blockade","volume":"28","author":"Riaz","year":"2016","journal-title":"Int Immunol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"Mcgranahan","year":"2017","journal-title":"Cell"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/cells8101228","article-title":"The cGAS paradox: contrasting roles for cGAS-STING pathway in chromosomal instability","volume":"8","author":"Hong","year":"2019","journal-title":"Cells"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS-STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2018.07.034","article-title":"Non-canonical activation of the DNA sensing adaptor STING by ATM and IFI16 mediates NF-\u03baB signaling after nuclear DNA damage","volume":"71","author":"Dunphy","year":"2018","journal-title":"Mol Cell"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s12276-020-0416-y","article-title":"The cGAS\/STING\/TBK1\/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels","volume":"52","author":"Basit","year":"2020","journal-title":"Exp Mol Med"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jtho.2020.01.009","article-title":"STING pathway expression identifies NSCLC with an immune-responsive phenotype","volume":"15","author":"Della Corte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omtn.2018.11.003","article-title":"An analysis of the expression and association with immune cell infiltration of the cGAS\/STING pathway in pan-cancer","volume":"14","author":"An","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.4110\/in.2020.20.e10","article-title":"Immunotherapy for non-small cell lung cancer: current landscape and future perspectives","volume":"20","author":"Lim","year":"2020","journal-title":"Immune Netw"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.critrevonc.2013.06.011","article-title":"Lung cancer in never smokers: disease characteristics and risk factors","volume":"88","author":"Pallis","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s42764-020-00009-8","article-title":"Mechanisms of UV-induced mutations and skin cancer","volume":"1","author":"Pfeifer","year":"2020","journal-title":"Genome Instab Dis"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","article-title":"The multifaceted role of chromosomal instability in cancer and its microenvironment","volume":"174","author":"Bakhoum","year":"2018","journal-title":"Cell"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-020-2698-6","article-title":"Pervasive chromosomal instability and karyotype order in tumour evolution","volume":"587","author":"Watkins","year":"2020","journal-title":"Nature"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"16910","DOI":"10.1073\/pnas.1009843107","article-title":"Allele-specific copy number analysis of tumors","volume":"107","author":"Van Loo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2023031315391495400_","volume-title":"Genomics in the cloud: using Docker, GATK, and WDL in terra","author":"Van der Auwera","year":"2020"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21105\/joss.00861","article-title":"UMAP: Uniform Manifold Approxi-mation and Projection","volume":"3","author":"Mcinnes","year":"2018","journal-title":"J Open Source Software"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nature11935","article-title":"Replication stress links structural and numerical cancer chromosomal instability","volume":"494","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS-STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat Rev Genet"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.celrep.2019.09.065","article-title":"Cancer-Cell-Intrinsic cGAS expression mediates tumor immunogenicity","volume":"29","author":"Schadt","year":"2019","journal-title":"Cell Rep"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/2159-8290.CD-20-0387","article-title":"Metastasis and immune evasion from extracellular cGAMP hydrolysis","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s43018-020-0028-4","article-title":"Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity","volume":"1","author":"Carozza","year":"2020","journal-title":"Nat Cancer"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrclinonc.2017.198","article-title":"Determinants and clinical implications of chromosomal instability in cancer","volume":"15","author":"Sansregret","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/25292","article-title":"Genetic instabilities in human cancers","volume":"396","author":"Lengauer","year":"1998","journal-title":"Nature"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"2023031315391495400_","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"Mcgranahan","year":"2016","journal-title":"Science"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0047\/3180228\/crc-22-0047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/762\/3282533\/crc-22-0047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/762\/3282533\/crc-22-0047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T09:30:08Z","timestamp":1700818208000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/8\/762\/707417\/Classifying-cGAS-STING-Activity-Links-Chromosomal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,4]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0047","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545327","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550911","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550911.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545327.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}